BriaCell's Immunotherapy Shows Promise in Metastatic Breast Cancer

TL;DR

**BriaCell is a high-risk, high-reward biotech with promising early clinical data in metastatic breast cancer, but its pre-revenue status and reliance on third parties make it a speculative bet.**

AI Summary

BriaCell Therapeutics Corp. (BCTXZ) is a clinical-stage biotechnology company focused on novel immunotherapies for cancer. The company is advancing its Bria-IMT targeted immunotherapy in a pivotal Phase 3 study for metastatic breast cancer (NCT06072612), which has Fast Track Designation from the FDA. BriaCell reported benchmark-beating median overall survival of 13.4 months in its Phase 2 study of Bria-IMT with retifanlimab, compared to 6.7-9.8 months in literature. For patients treated with the Phase 3 formulation post-2022, median overall survival was 16.5 months. The company is also developing Bria-OTS, a personalized off-the-shelf immunotherapy, with a Phase 1/2 study (NCT06471673) showing complete resolution of a lung metastasis in one patient. In September 2024, BriaCell received positive feedback from the FDA for its Bria-PROS+ Pre-IND meeting for prostate cancer. The global market for cancer drugs is projected to reach nearly $441 billion by 2029, with over 42,170 breast cancer deaths projected in 2025 in the US.

Why It Matters

BriaCell's advancements in immunotherapy, particularly Bria-IMT for metastatic breast cancer, could significantly impact patient outcomes, offering hope where current therapies provide limited survival benefits of 5.9-9.8 months for heavily pre-treated patients. For investors, successful progression through the pivotal Phase 3 study and potential FDA approval could unlock substantial market value in the projected $441 billion global cancer drug market by 2029. The company's focus on personalized off-the-shelf immunotherapies like Bria-OTS also positions it competitively against larger pharmaceutical players like Bristol-Myers Squibb and Merck & Co., Inc., who are also active in the cancer immunotherapy space. Employees and customers stand to benefit from a company potentially bringing life-extending treatments to market, addressing a critical unmet medical need.

Risk Assessment

Risk Level: high — BriaCell is a pre-revenue clinical stage company with 'substantial doubt about our ability to continue as a going concern,' indicating significant financial instability. The company is 'heavily reliant on third-parties to carry out a large portion of our business,' which introduces external dependencies and potential operational risks. Furthermore, 'pre-clinical studies and initial clinical trials are not necessarily predictive of future results,' meaning the positive early data for Bria-IMT and Bria-OTS does not guarantee future success.

Analyst Insight

Investors should approach BriaCell with extreme caution, recognizing the significant 'going concern' risk and pre-revenue status. While the early clinical data for Bria-IMT and Bria-OTS is encouraging, it's crucial to monitor the progress of the pivotal Phase 3 study (NCT06072612) and any further financing activities closely before considering an investment.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $441 billion — projected global market for cancer drugs (expected by the end of 2029)
• 13.4 months — median overall survival for Bria-IMT in Phase 2 (in metastatic breast cancer patients vs. 6.7-9.8 months in literature)
• 16.5 months — median overall survival for Bria-IMT Phase 3 formulation (in Phase 2 patients treated post-2022)
• 319,750 — estimated new breast cancer diagnoses in US (in 2025)
• 42,170 — projected breast cancer deaths in US (in 2025)
• 30% — 5-year survival rate for metastatic breast cancer (for those with metastatic disease at diagnosis)
• 5.9-9.8 months — median survival for MBC patients with 2+ prior lines of therapy (indicates high unmet medical need)
• $94,477,705 — aggregate market value of common equity held by non-affiliates (as of January 31, 2025)
• 1,883,906 — common shares issued and outstanding (as of October 15, 2025)

Key Players & Entities

• BriaCell Therapeutics Corp. (company) — clinical-stage biotechnology company
• Bria-IMT (company) — targeted immunotherapy lead candidate
• FDA (regulator) — U.S. Food and Drug Administration
• Retifanlimab (company) — immune checkpoint inhibitor
• Incyte (company) — manufacturer of retifanlimab
• Bria-OTS (company) — personalized off-the-shelf immunotherapy
• Bria-PROS+ (company) — prostate cancer immunotherapy candidate
• National Cancer Institute (company) — source of cancer statistics
• IQVIA Institute (company) — source of global oncology market report
• Bristol-Myers Squibb Company (company) — competitor in cancer immunotherapy market

FAQ

Risk Factors

• FDA Approval Dependency [high — regulatory]: The company's success is heavily reliant on obtaining FDA approval for its Bria-IMT therapy. The pivotal Phase 3 study for metastatic breast cancer (NCT06072612) must be successfully completed and reviewed by the FDA. Failure to achieve approval would significantly impact the company's ability to commercialize its lead product.
• Competition in Cancer Immunotherapy [high — market]: The cancer drug market is projected to reach $441 billion by 2029, indicating a highly competitive landscape. BriaCell faces competition from established pharmaceutical companies and other biotechnology firms developing novel immunotherapies. The company's ability to differentiate its therapies and secure market share is crucial.
• Clinical Trial Execution and Timelines [high — operational]: The company's development pipeline depends on the successful and timely execution of clinical trials, including the ongoing Phase 3 study for Bria-IMT and the Phase 1/2 study for Bria-OTS (NCT06471673). Delays or adverse outcomes in these trials could significantly impact development timelines and financial resources.
• Need for Additional Funding [high — financial]: As a clinical-stage biotechnology company, BriaCell likely requires substantial ongoing funding for research, development, clinical trials, and potential commercialization. The company's ability to secure future financing is critical for its continued operations and growth.
• Fast Track Designation Limitations [medium — regulatory]: While Bria-IMT has received Fast Track Designation from the FDA, this designation is intended to expedite the review process and does not guarantee eventual approval. The company must still meet all FDA requirements for safety and efficacy.
• Unmet Medical Need in Metastatic Breast Cancer [high — market]: Despite advancements, metastatic breast cancer (MBC) presents a significant unmet medical need. The 5-year survival rate for MBC is around 30%, and median survival for patients with 2+ prior lines of therapy can be as low as 5.9-9.8 months. BriaCell's therapies aim to address this, but success is not guaranteed.
• Reliance on Key Personnel [medium — operational]: The success of a biotechnology company often depends on the expertise of its key scientific and management personnel. The loss of key individuals could disrupt research, development, and strategic operations.
• Burn Rate and Cash Runway [high — financial]: Clinical-stage biotechs typically have high operating expenses (burn rate) with limited or no revenue. The company's cash position and its ability to extend its cash runway through financing or partnerships are critical for survival.

Industry Context

BriaCell operates in the rapidly growing cancer drug market, projected to reach $441 billion by 2029. The field of cancer immunotherapy is at the forefront, leveraging the body's immune system to fight disease. Key areas of focus include novel immunotherapies and personalized treatments, with significant unmet needs remaining in advanced cancers like metastatic breast cancer.

Regulatory Implications

The company's primary regulatory hurdle is obtaining FDA approval for its lead candidate, Bria-IMT, based on the pivotal Phase 3 study. Fast Track Designation offers a potential pathway for expedited review, but rigorous safety and efficacy data will be paramount. Positive feedback on the Bria-PROS+ Pre-IND meeting suggests a constructive dialogue with the FDA for future pipeline development.

What Investors Should Do

1. Monitor Phase 3 Bria-IMT trial progress and FDA communications.
2. Assess the company's cash runway and future financing needs.
3. Evaluate competitive landscape and Bria-IMT's differentiation.
4. Track developments in the Bria-OTS platform and other pipeline candidates.

Key Dates

• 2024-09-01: Received positive feedback from FDA for Bria-PROS+ Pre-IND meeting — Indicates potential for future development and regulatory pathway for prostate cancer therapy.
• 2022-01-01: Phase 3 formulation of Bria-IMT used in Phase 2 patients — Led to improved median overall survival of 16.5 months, suggesting formulation enhancements.
• N/A: Phase 3 study of Bria-IMT in metastatic breast cancer (NCT06072612) ongoing — This pivotal study is critical for potential FDA approval and commercialization.
• N/A: Phase 1/2 study of Bria-OTS (NCT06471673) ongoing — Demonstrates progress in personalized off-the-shelf immunotherapy platform.
• N/A: Phase 2 study of Bria-IMT with retifanlimab completed — Reported benchmark-beating median overall survival of 13.4 months, supporting the therapy's potential.
• N/A: Bria-IMT has Fast Track Designation from FDA — Accelerates potential review process for a treatment addressing an unmet medical need.

Glossary

Immunotherapy

A type of cancer treatment that harnesses the body's own immune system to recognize and destroy cancer cells. (This is the core technology platform of BriaCell Therapeutics.)

Bria-IMT

BriaCell's targeted immunotherapy currently in a pivotal Phase 3 study for metastatic breast cancer. (This is the company's lead product candidate.)

Immune Checkpoint Inhibitor

A type of drug that blocks proteins called checkpoints that prevent the immune system from attacking cancer cells. (Bria-IMT is studied in combination with an immune checkpoint inhibitor (Retifanlimab).)

Metastatic Breast Cancer (MBC)

Breast cancer that has spread to other parts of the body. (This is the primary indication for Bria-IMT in the ongoing Phase 3 study.)

Fast Track Designation

An FDA designation intended to expedite the development and review of drugs for serious conditions that fill an unmet medical need. (Bria-IMT has received this designation, potentially speeding up its path to market.)

Bria-OTS

BriaCell's personalized off-the-shelf immunotherapy platform. (Represents a second major development platform for the company.)

Pre-Investigational New Drug (Pre-IND) Application

A meeting with the FDA to discuss proposed clinical investigations before submitting a formal IND application. (Positive feedback from a Pre-IND meeting for Bria-PROS+ indicates a favorable regulatory outlook for prostate cancer therapy.)

Overall Survival (OS)

The length of time from diagnosis or treatment for a disease that patients are still alive. (Key metric used to demonstrate the efficacy of Bria-IMT, with BriaCell reporting improved OS compared to literature.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available from the provided text excerpt of the 10-K. The filing focuses on the current business operations, risk factors, and financial condition without direct year-over-year comparisons in this section.

Key Financial Figures

• $50.20 — liates based on a closing sale price of $50.20 per share, which was the last sale pric
• $441 billion — rapy drugs) is expected to reach nearly $441 billion by the end of 2029. 1 "Pivotal" is an

Filing Documents

• form10-k.htm (10-K) — 2344KB
• ex19-1.htm (EX-19.1) — 64KB
• ex21-1.htm (EX-21.1) — 4KB
• ex23-1.htm (EX-23.1) — 3KB
• ex31-1.htm (EX-31.1) — 17KB
• ex31-2.htm (EX-31.2) — 17KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• ex97-1.htm (EX-97.1) — 48KB
• image_001.jpg (GRAPHIC) — 69KB
• image_007.jpg (GRAPHIC) — 19KB
• image_008.jpg (GRAPHIC) — 80KB
• image_009.jpg (GRAPHIC) — 29KB
• image_010.jpg (GRAPHIC) — 34KB
• image_018.jpg (GRAPHIC) — 88KB
• image_012.jpg (GRAPHIC) — 1KB
• image_013.jpg (GRAPHIC) — 37KB
• image_014.jpg (GRAPHIC) — 73KB
• image_015.jpg (GRAPHIC) — 26KB
• image_016.jpg (GRAPHIC) — 35KB
• image_021.jpg (GRAPHIC) — 150KB
• form10-k_009.jpg (GRAPHIC) — 13KB
• form10-k_010.jpg (GRAPHIC) — 6KB
• form10-k_012.jpg (GRAPHIC) — 28KB
• aud_001.jpg (GRAPHIC) — 2KB
• 0001493152-25-018212.txt ( ) — 12292KB
• bctx-20250731.xsd (EX-101.SCH) — 67KB
• bctx-20250731_cal.xml (EX-101.CAL) — 76KB
• bctx-20250731_def.xml (EX-101.DEF) — 309KB
• bctx-20250731_lab.xml (EX-101.LAB) — 527KB
• bctx-20250731_pre.xml (EX-101.PRE) — 452KB
• form10-k_htm.xml (XML) — 1913KB

Business

Business 4 Item 1A

Risk Factors

Risk Factors 30 Item 1B Unresolved Staff Comments 47 Item 1C Cybersecurity 47 Item 2

Properties

Properties 47 Item 3

Legal Proceedings

Legal Proceedings 47 Item 4 Mine Safety Disclosures 47 PART II Item 5 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 48 Item 6 [Reserved] 48 Item 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 48 Item 7A

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 53 Item 8

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 53 Item 9 Changes In and Disagreements with Accountants on Accounting and Financial Disclosure 53 Item 9A

Controls and Procedures

Controls and Procedures 54 Item 9B Other Information 54 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 54 PART III Item 10 Directors, Executive Officers, and Corporate Governance 55 Item 11

Executive Compensation

Executive Compensation 64 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 66 Item 13 Certain Relationship and Related Transactions, and Director Independence 68 Item 14 Principal Accountant Fees and Services 68 PART IV Item 15 Exhibits 69 Item 16 Form 10-K Summary 72

SIGNATURES

SIGNATURES 73 2 Forward-Looking This Annual Report on Form 10-K contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements may be identified by such forward-looking terminology as "may," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks in the section titled " Risk Factors ", that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In addition, you are directed to factors discussed in the " Business " section and the " Management's Discussion and Analysis of Financial Condition and Results of Operations " section, as well as those discussed elsewhere in this Annual Report on Form 10-K. All of our forward-looking statements are as of the date of this Annual Report on Form 10-K only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such ex

BUSINESS

BUSINESS Overview of the Company BriaCell Therapeutics Corp. ("Briacell" or the "Company") is a clinical-stage biotechnology company that is developing novel immunotherapies to transform cancer care. Immunotherapies have come to the forefront in the fight against cancer as they harness the body's own immune system to recognize and destroy cancer cells. The Company is currently advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal 1 Phase 3 study in metastatic breast cancer (listed on ClinicalTrials.gov as NCT06072612 ). Bria-IMT is currently under Fast Track Designation by the U.S. Food and Drug Administration (the "FDA") intended to accelerate the review process of novel treatments that address unmet medical needs. Positive completion of the pivotal study, following review by FDA, could lead to full approval of the Bria-IMT immune checkpoint inhibitor combination in metastatic breast cancer. BriaCell has reported benchmark-beating patient survival and clinical benefit in metastatic breast cancer with median overall survival of 13.4 months in BriaCell's metastatic breast cancer patients vs. 6.7-9.8 months 2 for similar patients reported in the literature in its Phase 2 study of Bria-IMT combination study with retifanlimab. Additionally, BriaCell reported median overall survival of 16.5 months in Phase 2 Bria-IMT study patients treated in combination with immune checkpoint inhibitor in patients treated with the Phase 3 formulation since 2022 (post-COVID). A completed Bria-IMT Phase 1/2 combination study with retifanlimab (an anti-PD1 antibody manufactured by Incyte) confirmed tolerability and early-stage efficacy (listed on ClinicalTrials.gov as NCT03328026 ). BriaCell Phase 1/2 Study of Bria-OTS, BriaCell's personalized off-the-shelf immunotherapy, also known as Bria-BRES, in metastatic breast cancer is ongoing (listed on ClinicalTrials.gov as NCT06471673 ). The first patient treated with

View Full Filing

View this 10-K filing on SEC EDGAR